Immune cell ratios can help identify high-risk patients with glioma who have poor functional outcomes and shorter overall survival (OS), a new study finds.
Immune cell ratios in the glioma microenvironment are thought to reflect the systemic response to the tumor, according to researchers at the Royal Melbourne Hospital in Melbourne, Australia.
“Given the dearth in clinically significant molecular markers to predict prognosis, there is potential for immune cell ratios to serve as low-cost and readily available prognostic markers,” they noted.